|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 384.32 USD | +4.49% |
|
+12.41% | +17.42% |
| Feb. 06 | Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating | MT |
| Feb. 06 | Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating | MT |
Evolution of the Average Target: Amgen Inc.
Evolution of the Target Price: Amgen Inc.
Changes in Analyst Recommendations: Amgen Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | -11.03% | |||||
| +12.1% | |||||
| -3.64% | |||||
| +9.8% | |||||
| -1.43% | |||||
| -0.54% | |||||
| +9.11% | |||||
| -5.26% | |||||
| +30.61% | |||||
| -8.55% | |||||
| Average | +3.12% | |||||
| Weighted average by Cap. | +4.27% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Guggenheim | |
| Argus | |
| Deutsche Bank Securities | |
| TD Cowen | |
| Leerink Partners | |
| Citigroup | |
| Cantor Fitzgerald | |
| RBC Capital Markets | |
| Goldman Sachs | |
| Morgan Stanley | |
| Oppenheimer | |
| UBS | |
| Bernstein | |
| Wells Fargo Securities | |
| HSBC | |
| BMO Capital | |
| Daiwa Securities | |
| Piper Sandler | |
| Scotiabank | |
| DZ Bank | |
| DBS Bank | |
| Rothschild & Co Redburn | |
| Mizuho Securities | |
| BofA Securities | |
| Truist Securities | |
| Jefferies & Co. | |
| Redburn Atlantic | |
| JPMorgan Chase | |
| Barclays | |
| William Blair & Co. | |
| Baird | |
| Credit Suisse | |
| DA Davidson | |
| SVB Securities LLC | |
| Cowen | |
| Atlantic Equities | |
| SVB Leerink | |
| JPMORGAN | Cory Kasimov |
| RBC | Kennen Mackay |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
- Consensus Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
